NewsXbrane Biopharma releases interim report for the period January – March 2017

Xbrane Biopharma ABs interim report for the period January – March 2017 is now available on the Company’s website, www.xbrane.com

Period January – March

  • Net sales SEK 6,840 thousand (854)
  • Total income SEK 6,980 thousand (861)
  • Earnings before tax SEK -10,134 thousand (-5,530)
  • Cash flow from current operations SEK -9,353 thousand (-7,556)
  • Earnings per share before dilution SEK -2.19 (-2.48)

Significant events during the period

  • Xbrane received GMP certificate for the Spherotide production facility in Italy from AIFA (Italian Medicines Agency).
  • Xbrane delivered its first batch of Spherotide to a value of SEK 7 million to its partner in the Middle East.
  • Xbrane reported positive comparative pre-clinical data on Xlucane.

Significant events after the period

  • Xbrane reported positive comparative in vivo effect data on Spherotide.
  • Xbrane recruits Susanna Helgesen as new CFO / Head of Investor Relations.

For further information, please contact:

Martin Åmark
Chief Executive Officer
Tel: +46 (0) 763-093 777
E-mail: martin.amark@xbrane.com

Susanna Helgesen
CFO/IR
Tel: +46 (0) 708-278 636
E-mail: susanna.helgesen@xbrane.com